Protecting Intellectual Property in Engagements with CMOs
Publication
Article
BioPharm InternationalBioPharm International-06-15-2015
Volume 2015 eBook
Issue 1
Important IP contractual provisions should be included when working with CMOs.
Biotechnology and pharmaceutical companies often engage contract CMOs to assist with the development of their drugs. This type of arrangement naturally involves the development of intellectual property (IP), so it is important for both the CMO and the sponsor to identify pre-existing intellectual property and also define how rights to new IP will be allocated, protected, and enforced by and between the companies.
Download
BioPharm International’s 2015 Outsourcing Resources eBook.
Related Content
